Gencurix젠큐릭스
229000 · KOSDAQ · ₩229000 · 젠큐릭스
- Market cap
- ₩46B
- Enterprise value
- ₩46B
- P/E
- —
- P/B
- 3.6×
- Dividend yield
- 0.0%
- ROE
- −59.6%
- Net margin
- −84.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−73.3% from the high
₩1,321Today: ₩1,957 – ₩1,957₩7,320
Returns
- 1W0.0%
- 1M0.0%
- 3M+24.5%
- 6M−16.2%
- YTD+26.2%
- 1Y+27.5%
- Volume today
- —
- Traded today
- —
- Listed shares
- 23,428,165
- EPS (12 months)
- −₩320
- Earnings yield −16.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Gencurix stock overview
Gencurix (젠큐릭스, KRX: 229000) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops liquid biopsy-based molecular diagnostic tests, mainly for cancer, using DNA and RNA analysis. Its shares closed at ₩1,957 on Oct 26, 2026, unchanged on the day, giving it a market value of ₩46B.
Key facts
- Market cap
- ₩46B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 26, 2026
- Main business
- The company develops liquid biopsy-based molecular diagnostic tests, mainly for cancer, using DNA and RNA analysis.
Quick answers about Gencurix
- What does Gencurix do?
- The company develops liquid biopsy-based molecular diagnostic tests, mainly for cancer, using DNA and RNA analysis. Its main products include GenesWell BCT, a breast cancer prognostic test, and the Droplex series of companion diagnostic tests for cancers such as lung, thyroid, colorectal, and endometrial cancer, which are offered to hospitals and laboratories in Korea and sold overseas through distributors and remote testing services.
- What is the market cap of Gencurix?
- The market capitalisation of Gencurix was ₩46B at the close on Oct 26, 2026.
- Who are the largest shareholders of Gencurix?
- According to the latest official filings, the largest reported holders are Jo Sang-rae (36.45%, as of Jul 14, 2026); Geumseong Baekjo Housing (4.85%, as of Jan 28, 2026); National Pension Service (0.81%, as of Dec 31, 2023).
- When is the next earnings report from Gencurix?
- Korean companies rarely announce results dates in advance. Based on when Gencurix filed the same report in past years, its next 3q results is expected between Nov 12, 2026 and Nov 14, 2026.
- Does the National Pension Service own Gencurix?
- Yes. The National Pension Service held 0.81% of Gencurix shares as of Dec 31, 2023.
Company profile
The company develops liquid biopsy-based molecular diagnostic tests, mainly for cancer, using DNA and RNA analysis. Its main products include GenesWell BCT, a breast cancer prognostic test, and the Droplex series of companion diagnostic tests for cancers such as lung, thyroid, colorectal, and endometrial cancer, which are offered to hospitals and laboratories in Korea and sold overseas through distributors and remote testing services.
Written by AI from the company's latest annual report.
- Korean name
- 젠큐릭스
- Sector
- Biotech & Pharma
- CEO
- 조상래
- Founded
- Sep 2011
- Listed
- Jun 2020
- Listed shares
- 23,428,165
- Fiscal year ends
- Month 12
- Website
- www.gencurix.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Amended: Merger decisionOct 22, 2026
- Other Market Notice (Extension of Investigation Period to Determine Whether Substantive Review Applies)Oct 12, 2026
- [Amended Filing] Major Matters Report (Business Suspension)Oct 7, 2026
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Sep 30, 2026
- Amended: Merger decisionSep 23, 2026
Titles in Korean until English translations are added.
Also known as: Gencurix / 젠큐릭스 / 229000 / KRX:229000
Source: KRX statistical information